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An important objective of pain research is to identify novel drug
targets for the treatment of pathological persistent pain states, such as
inﬂammatory and neuropathic pain. Mas-related G-protein–coupled
receptors (Mrgprs) represent a large family of orphan receptors specif-
ically expressed in small-diameter nociceptive primary sensory neu-
rons. To determine the roles of Mrgprs in persistent pathological
pain states, we exploited a mouse line in which a chromosomal locus
spanning 12 Mrgpr genes was deleted (KO). Initial studies indicated
that these KO mice show prolonged mechanical- and thermal-pain
hypersensitivity after hind-paw inﬂammation compared with wild-
type littermates. Here, we show that this mutation also enhances
the windup response of dorsal-horn wide dynamic-range neurons,
an electrophysiological model for the triggering of central pain sensi-
tization. Deletion of theMrgpr cluster also blocked the analgesic effect
of intrathecally applied bovine adrenal medulla peptide 8–22 (BAM 8–
22), an MrgprC11 agonist, on both inﬂammatory heat hyperalgesia
and neuropathic mechanical allodynia. Spinal application of bovine
adrenal medulla peptide 8–22 also signiﬁcantly attenuated windup
inwild-typemice, an effect eliminated in KOmice. These data suggest
that members of the Mrgpr family, in particular MrgprC11, may con-
stitute an endogenous inhibitory mechanism for regulating persistent
pain in mice. Agonists for these receptors may, therefore, represent
a class of antihyperalgesics for treating persistent pain with minimal
side effects because of the highly speciﬁc expression of their targets.
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After tissue inﬂammation or nerve injury, increased afferentneuronal excitability (peripheral sensitization) and a state of
dorsal-horn neuronal hyperexcitability (central sensitization) am-
plify ascending pain signals (1, 2), which, if uncontrolled, may lead
to various unremitting pain symptoms (e.g., tactile allodynia, ther-
mal hyperalgesia, or spontaneous pain) in a subset of patients (3, 4).
Patientswith suchpersistentpain stateshave few treatmentoptions,
in part because pain-speciﬁc drug targets are lacking (4, 5). One set
of potential targets comprises a large family of orphan receptors
known as Mas-related G-protein–coupled receptors (Mrgprs).
Many Mrgprs (e.g., As, B4, B5, C11, and D) are expressed speciﬁ-
cally on small-diameter, presumably nociceptive, nonpeptidergic
sensory neurons in the dorsal root ganglia (DRG) (6, 7). Recent
studies have begun to shed light on the physiological functions
served by Mrgprs, including mediation of nonhistaminergic itch by
MrgprA3 (8–11). Whether other Mrgprs mediate itch or regulate
persistent pathological pain states is not clear (12–14).
Examining the function of Mrgprs in vivo has been challenging,
because endogenous Mrgpr ligands have not been unequivocally
identiﬁed and deletion of a single Mrgpr gene may not cause
a detectable phenotype because of potential redundancy in the
Mrgpr gene family (7, 15). To overcome these problems, we gen-
erated a mouse line in which 12 intact Mrgpr coding sequences
(As, B4, B5, and C11) were simultaneously deleted; the resulting
mice are referred to as Mrgpr-clusterΔ−/− (KO) mice (11). The
deleted cluster contains most MrgprA and MrgprC genes and
represents ∼50% of the potentially functional Mrgpr repertoire in
mice (7). Importantly, the deleted Mrgprs are not required for
neuronal survival or fate determination of small-diameter sensory
neurons (11). Therefore, the KOmice may represent a useful tool
for studying the functions and determining the roles of Mrgprs in
pain in vivo. The KO mice respond normally to acute noxious
thermal, mechanical, and chemical stimuli compared with wild-
type (WT) littermates. However, they display prolonged mechan-
ical- and thermal-pain hypersensitivity after intraplantar injection
of complete Freund’s Adjuvant (CFA) or carrageenen, whereas
the development of neuropathic pain was similar between the two
genotypes (11). Findings from our previous work motivated us to
further examine the roles for Mrgprs in signaling and modulation
of persistent pain states with different origins (i.e., inﬂammation
and nerve injury) and investigate the underlying neurophysiologi-
cal mechanisms in vivo. We also tested the effect of intrathecal
administration of an MrgprC11 agonist, bovine adrenal medulla
peptide 8–22 (BAM 8–22), on mouse pain behavior. Our results
suggest that certain Mrgprs in mice may constitute endogenous
inhibitors of pathological pain. These data also suggest that ago-
nists, rather than antagonists, for MrgprC11 may represent a class
of antihyperalgesics for persistent pain.
Results
Intense/Repetitive Noxious Input Activates an Endogenous Mrgpr
Mechanism to Counteract the Sensitization of Pain Responses. First,
we examined whether formalin-induced tissue injury leads to an
endogenous activation of Mrgprs to modulate spontaneous pain.
The formalin test is a unique model of persistent pain that
encompasses inﬂammatory, neurogenic, and central mechanisms
of nociception (16–18). Importantly, spontaneous pain responses
to two principally different stimuli, nociceptor activation (ﬁrst
phase) and tissue inﬂammation (second phase), can be readily
revealed in the same test and separately analyzed. Formalin (2%;
5 μL) was injected into the plantar tissue of one hind paw. We
observed that spontaneous pain behavior in the second phase
(10–60 min post injection), which is driven largely by tissue in-
ﬂammation and involves central sensitization of dorsal-horn
neurons (16), was signiﬁcantly potentiated in KO mice compared
with WT littermates (Fig. 1A). Reﬂecting this behavioral phe-
notype, a greater increase of c-fos–expressing neurons in the
ipsilateral laminae I and II of lumbar (L4–L6) spinal segments in
KO mice than in WT mice was evident after an intraplantar
injection of formalin (Fig. 1B). In contrast, the ﬁrst (acute) phase
of the formalin response (0–10 min post injection), which results
predominantly from a direct chemical stimulation of the C ﬁber-
afferent nociceptors, was not affected by the mutation (Fig. 1A).
Next, we examined whether the enhanced inﬂammatory-pain
response in KO mice is also manifested at the cellular level of
spinal pain processing. Wide dynamic-range (WDR) neurons in
the deep dorsal horn are important for spinal pain processing and
are candidates for transmission cells in the gate theory of pain (2,
19, 20). They receive both innocuous and noxious sensory inputs
from the periphery and display A ﬁber- and C ﬁber-mediated
responses (A and C components, respectively) to a single in-
tracutaneous electrical stimulus with an intensity above C ﬁber-
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activation threshold (Fig. 2A). Based on the axon-conduction
velocities, WDR neuronal responses to electrical stimuli in mice
were separated into a short latency A component (0–40 ms, ex-
cluding stimulus artifact) and a long latency C component (40–
250 ms) (20). Typically, the excitability of some WDR neurons
progressively increases in response to repetitive C ﬁber-afferent
stimulation, a short-term activity-dependent neuronal sensitiza-
tion called windup (21). Therefore, we recorded from WDR
neurons and examined whether the deletion of the Mrgpr cluster
would alter the excitability of WDR neurons. The effective
frequency of the electrical stimulation for inducing windup is
usually >0.3 Hz under physiological conditions, and a plateau
level of windup is often reached at a higher-frequency stimulation
of ∼1 Hz (20, 21). Accordingly, windup was examined by re-
petitive intracutaneous electrical stimuli (16 pulses, 3.0 mA/supra
C ﬁber-activation threshold, 2.0 ms) applied at 0.2 and 1.0 Hz,
with a minimum 10-min interval between each trial. We observed
that WDR neurons in WT mice (n = 23) showed windup
responses at the higher frequency of 1.0-Hz stimulation but rarely
at 0.2-Hz stimulation (Fig. 2 B and D), consistent with previous
studies (20, 21). To quantify the peak levels of windup, we mea-
sured the relative windup value, which is the averaged C com-
ponent responses to the last 10 (7–16) stimuli of the trial
normalized by the C component response to the ﬁrst stimulus of
each trial (input value). The relative windup values were signiﬁ-
cantly increased during 1.0- but not 0.2-Hz stimulation in WT
mice compared with the respective baseline (Fig. 2E). Strikingly,
unlike the case inWTmice, manyWDRneurons in KOmice (n=
30) exhibited windup at the normally ineffective 0.2-Hz stimula-
tion frequency (Fig. 2 B and D), and the relative windup value at
0.2-Hz stimulation in the KO group was signiﬁcantly greater than
the baseline (Fig. 2E). Importantly, the windup responses at both
0.2- and 1.0-Hz stimulation frequencies were signiﬁcantly greater
in KO than in WT mice (P < 0.05) (Fig. 2E). The mean recording
depth of WDR neurons did not differ betweenWT (450 ± 23 μm)
and KO mice (441 ± 22 μm, P > 0.05). In contrast with their
differences in windup, the acute responses of WDR neurons to
graded intracutaneous electrical stimulation (0.05–5.0 mA, 2.0
ms) were comparable between the WT and KO mice. The
threshold and population stimulus-intensity response (S-R)
functions of the C component were also similar in the two groups
(Fig. 2C and Table 1). These data suggest that one or more
Mrgprs within the KO cluster function to limit the extent of in-
creased WDR neuronal excitability in response to repetitive C
ﬁber stimulation.
Intrathecal Administration of BAM8–22 Inhibits Persistent Inﬂammatory
and Neuropathic Pain inWT but Not KOMice.One gene within the KO
cluster that can potentially modulate pain responses is MrgprC11.
An endogenous agonist of MrgprC11 is a 22-amino acid peptide
called BAM 22 (6, 7); it belongs to the family of endogenous opioid
peptides and is derived from the proenkephalin A gene. In-
terestingly, the N terminus of BAM 22 binds and activates opioid
receptors, whereas the C terminus of the peptide activates mouse
MrgprC11, rat MrgprC, and human MrgprX1. Previous studies
have shown that a truncated BAM 22, which lacks its N terminus
(BAM 8–22), speciﬁcally activates Mrgprs but not opioid receptors
(6, 14). Importantly, among the 12Mrgprs deleted inMrgpr-cluster
KOmice, onlyMrgprC11 is activated byBAM8–22 in heterologous
cells (9, 11, 14). In rats, several rodent MrgprC agonists, including
BAM 8–22 and γ2-melanocyte-stimulating hormone (γ2-MSH),
have been reported to have both pro- and antipain effects (12, 13,
22–25). Because these previous studies did not use transgenic
Fig. 1. KO mice display stronger dorsal-horn neuronal activation and en-
hanced pain responses after intraplantar formalin injection. (A) KO mice
expressed enhanced spontaneous pain responses in the second phase of for-
malin-induced pain but responded normally in the ﬁrst (acute) phase.
(B) Transverse sections of L4–L5 spinal cord fromWT and KOmice were stained
with anti–c-fos antibody 3 h after intraplantar formalin injection (2%, 5 μL).
Ten sections were chosen randomly from each mouse (three mice per geno-
type). c-fos–positive nuclei are indicated by arrows. KO mice had signiﬁcantly
more c-fos–positive cells than did WT mice, indicating that the KO mice had
greater neuronal activation. Data are expressed as mean ± SEM.
Fig. 2. WDRneurons inKOmicedisplay enhancedwindup to repetitive Cﬁber
input. (A) A WDR neuron displayed typical A component (0–40 ms) and
C component (40–250 ms) responses in response to suprathreshold in-
tracutaneous electrical stimulation. This unit from a KO mouse showed pro-
gressive increases in C component (windup) in response to repetitive electrical
stimulation of 0.2 Hz (16 pulses, 3.0 mA, 0.5 ms). (B) Histograms show responses
of WDR neurons from KO and WT mice to 0.2-Hz stimulation. The KO neuron
displayed windup, but the WT neuron did not. Bin size is 50 ms. APs, action
potentials. (C) Stimulus-response functionsofC components togradedelectrical
stimuli (0.1–5.0mA, 2.0ms) did not differ betweenWT (n = 23) andKOmice (n =
30). (D) C components of the responses to repetitivewindup-inducing electrical
stimulationappliedat0.2Hzand1.0Hz inWTandKOmicewereplottedagainst
the stimulation number of each trial. (E) The averaged C components of the
responses to the last 10 stimuli (7–16) of 0.2- and 1.0-Hz stimulation were sig-
niﬁcantly higher in KO than WT mice. Windup data are normalized to the re-
sponse evokedby theﬁrst stimulation of each trial. Data are presented asmean
± SEM. **P < 0.01 vs. the input value; #P < 0.05 vs. WT group.
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animals that lack Mrgprs and the speciﬁcity of these agonists for
Mrgprs has not been fully established, it has been difﬁcult to de-
termine whether the effects of these peptides in vivo are mediated
by Mrgprs.
Because the spinal cord is an important site for pain modu-
lation and Mrgprs are likely expressed on the central as well as
the peripheral terminals of DRG neurons (12, 13), we examined
the effects of intrathecal BAM 8–22 (1 mM, 5 μL) on pain be-
havior in WT and KOmice. This peptide on its own elicited mild,
short-lived (less than 5 min) scratching and tail-biting behavior in
some WT mice, but this response was similar in KO mice, sug-
gesting that it is not mediated by Mrgprs (or at least not by those
contained within the deleted cluster). We next examined the
ability of BAM 8–22 to modulate persistent inﬂammatory pain
by examining enhanced pain sensitivity to a noxious heat stim-
ulus as monitored by the Hargreaves test 24 h after intraplantar
injection of CFA (6 μL, 50%) into one hind paw. In the absence
of BAM 8–22, thermal hyperalgesia was comparable between the
two genotypes: the paw-withdrawal latencies (PWL) of the ipsi-
lateral hind paw in KO and WT mice were 4.3 ± 0.7 s and 3.3 ±
0.3 s, respectively. In WT mice, a single intrathecal injection of
BAM8–22 (1mM, 5 μL)was able to alleviate thermal hyperalgesia
at 30 min postinjection, increasing the PWL by 1.9-fold compared
with predrug baseline (Fig. 3A, WT, n = 13, ipsilateral paw). In
contrast, this antihyperalgesic effect of BAM 8–22 was not ob-
served in KO mice (Fig. 3A, KO, n = 10), indicating that it is
Mrgpr-dependent. In addition, intrathecal BAM 8–22 did not
signiﬁcantly affect the PWLof the contralateral (control side) hind
paw to acute radiant heat in either group (Fig. 3A, contralateral
paw). These data suggest that Mrgprs (most likely, Mrgpr C11)
play a role in mediating the effect of exogenously administered
BAM 8–22 to attenuate inﬂammatory thermal hyperalgesia in
WT mice.
To determine whether intrathecal BAM 8–22 also affects acute
thermal nociception, we performed tail-immersion tests in naïve
WT and KOmice. The tail-ﬂick latencies after intrathecal injection
of BAM 8–22 were not signiﬁcantly different from the respective
predrug values in either WT (n = 10) or KO mice (n = 10) (Fig.
3B). This ﬁnding is in line with the observation that the peptide did
not signiﬁcantly change the sensitivities to acute radiant heat
(Hargreaves test) inWT (n= 15) and KO (n= 14) (Fig. 3B) mice.
In addition, thermal sensitivities were comparable between the two
groups before and after BAM 8–22 treatment (Fig. 3B).
There are substantial differences between neuropathic-pain and
inﬂammatory-pain states (e.g., etiology, pathology, and treatment
strategy) (4, 26–28). Because mechanical allodynia is the most
common and disabling stimulus-evoked symptom of neuralgia and
is often difﬁcult to treat, we determined whether BAM 8–22 can
also reduce neuropathic mechanical allodynia in mice. We sub-
jectedmice to the chronic constriction-injury (CCI)model, inwhich
the sciatic nerve is ligated loosely with a suture. The effect of this
manipulation on mechanical-pain sensitivity was tested at 14–18
d after injury by measuring paw-withdrawal frequency to punctuate
mechanical stimuli of different strengths. Intrathecal injection of
BAM 8–22 (0.5 mM, 5 μL) signiﬁcantly attenuated CCI-induced
mechanical-pain hypersensitivity to both low-force (0.07 g) and
high-force (0.45 g) stimuli applied to the ipsilateral hind paw inWT
mice (Fig. 3C) (n = 7). This antihyperalgesic effect of the peptide
was eliminated in KO mice (Fig. 3C) (n = 8), although the de-
velopment of mechanical allodynia itself was not affected by the
mutation. BAM 8–22 did not signiﬁcantly change paw-withdrawal
responses on the uninjured side (Fig. 3D, contralateral paw). This
result suggests that the antiallodynic effect of intrathecal BAM 8–
22 under neuropathic conditions is also mediated by Mrgprs.
Spinal Application of BAM 8–22 Attenuates Windup in WT but Not KO
Mice. Next, we asked whether the antihyperalgesic effect of BAM
8–22 can be seen at the level of central nociceptive processing.
Because intrathecal BAM 8–22 inhibited both inﬂammatory and
neuropathic pain, we postulated that MrgprC11 agonists might
attenuate spinal neuronal sensitization involved in persistent
pain. We examined the effects of topical spinal application of
BAM 8–22 (0.1 mM, 30 μL) on the windup of WDR neuronal
responses to repetitive noxious inputs. We used 0.5-Hz stimula-
tion frequency, because it can induce windup but does not satu-
rate the response (21). Therefore, it can be used to examine the
effect of either facilitatory or inhibitory drug action on windup. In
WTmice (n= 25), windup to 0.5-Hz stimulation was signiﬁcantly
attenuated after spinal superfusion with BAM 8–22 (Fig. 4 A–C,
WT), consistent with the antihyperalgesic effect of BAM 8–22 in
our behavioral studies. In KO mice, by contrast, the effect of
BAM 8–22 was not simply eliminated but rather, reversed: the
Table 1. The thresholds and latency of the ﬁrst A and C ﬁber-
mediated action potentials in WDR neurons
A latency
(ms)
C latency
(ms)
A threshold
(mA)
C threshold
(mA)
WT 14.0 ± 0.8 124 ± 5 0.23 ± 0.04 2.0 ± 0.3
KO 14.8 ± 0.6 108 ± 6 0.26 ± 0.03 2.3 ± 0.2
WT pre-BAM 14.2 ± 0.8 114 ± 5 0.16 ± 0.02 1.5 ± 0.3
WT post-BAM 12.1 ± 0.7 115 ± 4 0.17 ± 0.03 1.7 ± 0.4
KO pre-BAM 14.5 ± 0.6 126 ± 3 0.17 ± 0.02 1.7 ± 0.5
KO post-BAM 12.9 ± 0.6 118 ± 4 0.19 ± 0.03 1.9 ± 0.6
WT,wild type; KO,Mrgpr-cluster −/−; BAM, BAM8-22.Data aremean± SEM.
Fig. 3. Intrathecal injection of BAM 8–22 inhibits persistent inﬂammatory
pain and neuropathic pain in WT but not KO mice. (A) Intrathecal (i.th.) in-
jection of BAM 8–22 (1mM, 5 μL) signiﬁcantly alleviated thermal hyperalgesia
in the ipsilateral hind paw 24 h after intraplantar injection of CFA (6 μL, 50%)
in WT (n = 12) but not KO mice (n = 10). BAM 8–22 did not affect PWL of the
contralateral hind paw in either group. (B) The same dose of BAM 8–22 did
not signiﬁcantly change the tail-ﬂick latency in the tail-immersion test (50 °C)
inWT (n = 10) or KOmice (n = 10). In addition, the tail-ﬂick latencies were not
signiﬁcantly different between the two groups at pre- and postdrug con-
ditions. PWL of the contralateral hind paw to radiant heat (Hargreaves test)
in the CFA experiment was similar before and after intrathecal BAM 8–22
injection in both groups. (C) BAM 8–22 (0.5 mM, 5 μL, i.th.) also attenuated
mechanical-pain hypersensitivity induced by CCI of the sciatic nerve in WT
mice but not KO mice. The PWF of the ipsilateral hind paw to low-force (0.07
g) and high-force (0.45 g) punctuate stimulation was signiﬁcantly increased
from the preinjury levels in both KO and WT mice 14–18 d postinjury. BAM
8–22 signiﬁcantly reduced the PWF of the ipsilateral hind paw in response to
low- and high-force stimuli in WT mice (n = 7) but not KO mice (n = 8) after
30 min. (D) BAM 8–22 did not signiﬁcantly reduce the PWF of the contralat-
eral hind paw in either group. Data are expressed as mean ± SEM. *P < 0.05
and **P < 0.01 vs. preinjury value; ##P < 0.01 vs. predrug value.
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peptide signiﬁcantly increased the input value and C component
responses of WDR neurons to 0.5-Hz stimulation (Fig. 4A, cf
WT vs. KO, black squares). Population S-R functions of C ﬁber-
mediated responses of WDR neurons to graded electrical stim-
ulation were similar before and after drug administration in WT
mice (n = 25) (Fig. 4D). However, in KO mice, BAM 8–22 sig-
niﬁcantly increased the number of C component responses to
graded electrical stimulation at intensities >1.0 mA (n= 17) (Fig.
4D). Nevertheless, the threshold and latency of the ﬁrst C ﬁber-
mediated action potential was unaffected by administration of the
peptide in either WT or KOmice (Table 1). These results suggest
that the inhibitory effects of BAM 8–22 on windup, a measure of
short-term neuronal hyperexcitability, are mediated by Mrgprs.
Furthermore, deletion of Mrgprs unmasks a potentiating effect of
the peptide on the same response mediated by another class
of receptors.
Discussion
Receptors Within a Cluster of Mrgprs May Mediate an Endogenous
Inhibitory Mechanism for Persistent Pain and Hyperalgesia. Our
previous behavioral studies indicated that deletion of the Mrgpr
gene cluster exaggerates inﬂammatory-pain responses while leav-
ing acute nociceptive-pain sensation intact (11), but it left open the
question of the underlying neurobiological mechanism(s). Intense
nociceptor activation through C ﬁber-evoked responses in dorsal-
horn neurons results in a state of central sensitization manifested
as an increased neuronal response to subsequent stimuli (2, 29).
The windup phenomenon in WDR neurons reﬂects an activity-
dependent short-term increase in neuronal excitability (21, 30, 31).
Like many biological functions, the windup response to changes in
stimulation frequency may be represented by a sigmoidal function.
We postulate that a facilitation of windup by removal of endoge-
nous inhibition is manifested as a reduction in the effective-
frequency threshold for eliciting this response from 1.0- to 0.2-Hz
stimulation. A similar phenotype was observed in mice lacking the
μ-opioid–receptor gene (20). The facilitated windup in KOmice is
consistent with the enhanced inﬂammatory- and formalin-pain
behavioral phenotype. In contrast to windup, the acute responses
of WDR neurons to graded electrical stimulation (e.g., S-R func-
tion and threshold) were not signiﬁcantly different between the
two genotypes. These electrophysiological data suggest that the
encoding of acute noxious stimuli by WDR neurons is largely in-
tact in KO mice, consistent with the observation that KO mice
respond to nociceptive mechanical- and thermal-pain in a manner
similar to their WT littermates (Fig. 3 B–D).
Together, our behavioral and electrophysiological experiments
provide complementary lines of evidence that an endogenous
mechanism mediated by a cluster of Mrgprs inhibits persistent
pain behavior and a spinal electrophysiological correlate of
hyperalgesia, presumably by acting on sensory afferent ﬁbers in
the dorsal horn. Apparently, this Mrgpr-mediated pain inhibition
is not tonically active but is triggered only by intense noxious
inputs (e.g., by inﬂammation or repetitive electrical activation of
C ﬁbers), wherein it functions to attenuate pathological pain se-
verity and counteract dorsal-horn neuronal sensitization.
The identities of the speciﬁcMrgpr receptor and its endogenous
ligand that mediate this inhibitory inﬂuence inWTmice remain to
be determined, although MrgprC11 and BAM 22 are potential
candidates. A previous study has shown that BAM22 expression is
up-regulated in rat dorsal horn and small-sizedDRGneurons after
CFA-induced hind-paw inﬂammation (32). Future studies are
needed to determine whether changes in the expression of Mrgprs
also occur after tissue inﬂammation and nerve injury.
BAM 8–22 Inhibits Persistent Pain and Spinal Neuronal Sensitization
Through Activation of Mrgprs. In the current study, intrathecal ad-
ministration of BAM 8–22 suppressed thermal hyperalgesia in-
duced by hind paw inﬂammation in WT mice. This ﬁnding is in
accordance with previous observations in rats that intrathecal ad-
ministration of BAM 8–22 suppresses inﬂammatory pain and spi-
nal c-fos expression induced by intraplantar formalin injection (22,
32, 33) and diminishes NMDA-evoked nocifensive behaviors (12).
Importantly, the antihyperalgesic effect of intrathecal BAM 8–22
was not observed in KO mice, suggesting that the effect is Mrgpr-
dependent. Peripheral-nerve injury-induced mechanical allodynia
also was attenuated by intrathecal BAM 8–22 in WT mice but not
in KO mice. These ﬁndings show that spinal administration of
BAM 8–22 attenuates both thermal- and mechanical-pain hyper-
sensitivity in mice under different pathological conditions (tissue
inﬂammation and nerve injury), presumably through activation of
Mrgprs at central terminals of DRG neurons. Among the 12 de-
leted Mrgprs in Mrgpr-clusterΔ−/− mice, MrgprC11 likely con-
tributes most to the inhibitory effect, because BAM 8–22 is
a speciﬁc agonist of MrgprC11 (11, 14). However, additional
experiments that use mice with a single MrgprC11 deletion and
MrgprC11 rescue in cluster KO mice will be needed to directly
determine the role of MrgprC11 in the antihyperalgesic effect.
Because MrgprC11 is an ortholog of human MrgprX1, which can
also be activated by BAM 8–22 (6), BAM 8–22 delivered through
a spinal route may represent a promising treatment for patholog-
ical pain states. Notably, BAM 8–22 is unlikely to compromise
protective physiological pain, because it did not affect baseline
nociception (e.g., tail immersion test and paw withdrawal thresh-
old/latency on the uninjured side).
Fig. 4. BAM 8–22 inhibits windup in WT mice. (A) The C components of
WDR neuronal response to 0.5-Hz stimulation were plotted as a function of
stimulus number before and after BAM 8–22 administration. (B) The aver-
aged C component responses for the last 10 stimuli during 0.5-Hz stimulation
in WT mice were normalized by the respective response evoked by the ﬁrst
stimulation of each trial (input value). The relative windup in WT mice was
signiﬁcantly decreased by BAM 8–22 compared with the predrug level. Be-
cause of a signiﬁcant increase of input in KO mice after BAM 8–22 treat-
ment, windup data were not normalized. (C) The histograms show an
example of the inhibitory effect of BAM 8–22 on the windup of a WDR
neuron in WT mice at 0.5-Hz stimulation. The windup response was sub-
stantially attenuated 10–30 min after BAM 8–22 application and was par-
tially recovered 10–30 min after saline washout. Bin size is 50 ms. (D) BAM
8–22 (0.1 mM, 30 μL) signiﬁcantly increased the C component response to
graded electrical stimulation at intensities of 2.0–5.0 mA in KO (n = 17) but
not WT mice (n = 25) at 10–30 min after spinal topical application. Data are
expressed as mean ± SEM. *P < 0.05 and **P < 0.01 vs. the predrug condi-
tion; #P < 0.05 vs. the input value.
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An important site for integration of nociceptive information and
analgesic action is the dorsal horn (34–36). BAM8–22 signiﬁcantly
inhibited windup in WT mice but not in KO mice. These results
suggest that the inhibitory action of BAM 8–22 on windup in WT
mice isMrgpr-dependent.Major analgesics (e.g., opioids,NMDA-
receptor antagonists, and adenosine) that alleviate chronic pain
also exert a strong inhibition onwindup (21, 37, 38). Therefore, the
inhibition of windup by BAM 8–22 correlates well with its anti-
hyperalgesic effect on behavior. Unlike windup, the threshold and
S-R functions for C ﬁber-mediated responses inWDR neurons to
graded electrical stimuli were not signiﬁcantly changed byBAM8–
22 in WT mice, consistent with the fact that BAM 8–22 did not
affect baseline nociceptive-pain sensitivity in WT mice.
In KOmice, BAM 8–22 increased, rather than decreased, the C
ﬁber-mediated responses of WDR neurons to graded electrical
stimulation at intensities >1 mA, indicating a facilitatory effect of
BAM 8–22 on neuronal response to acute noxious input in the
absence of the Mrgpr cluster. This excitatory action of BAM 8–22
onWDRneuronsmaybemediated throughanMrgpr-independent
mechanism or by Mrgpr family members that were not part of the
deleted cluster. However, we do not think that BAM 8–22 should
increase acute peripheral-pain sensitivity in KO mice, because the
threshold for activation of the C component in WDR neurons did
not change after BAM8–22 treatment in thesemutants. Therefore,
the facilitatory effect of BAM8–22 seen inmutantWDRneurons is
likely caused by activation of a receptor(s) expressed in the spinal
cord (e.g., on WDR neurons themselves, interneurons, or
descending ﬁbers). The dual and opposing inﬂuences of BAM8–22
on pain transmission uncovered by our experiments may help to
reconcile some of the previous conﬂicting reports regarding the
effect of this peptide on pain behavior (13, 39).
Potential Mechanisms for Mrgpr-Mediated Pain Inhibition.Our study
suggests that activation of certainMrgprs normally suppresses the
WDR windup response and also attenuates behavioral hyper-
algesia. This might imply an inhibitory action of the relevant en-
dogenous ligand on the primary sensory neurons that express
these receptors. However, we previously observed an Mrgpr-
dependent increase in intracellular calcium levels after BAM 8–
22 treatment in DRG cells, which we proposed may underlie the
itch response induced by intradermal injection of BAM 8–22 in
WTmice (11). Although BAM 8–22 may activate different Mrgpr
family members in the periphery versus at central terminals, it is
also possible that this peptide might exert different effects on pain
and other sensations through the same receptor when applied at
different locations. For example, capsaicin, which excites DRG
neurons and induces intense burning pain in the periphery
through the receptor TrpV1, depresses presynaptic excitation and
inhibits pain when applied centrally (40, 41). This effect could
result from presynaptic terminal depolarization, which would
decrease the amplitude of action potentials and induce pre-
synaptic inhibition (42). Alternatively, BAM8–22mightmodulate
cellular activities differently at the cell body (e.g., pattern of ac-
tion-potential ﬁring) than at central terminals (e.g., neurotrans-
mitter release). Such differences could occur as a result of
disparate distributions and compartmentalization of Mrgprs, in-
tracellular signaling machinery (e.g., Gq andGi), and receptors or
channels (e.g., calcium channels) whose activity may be modu-
lated by Mrgpr activation (43, 44). In light of the important roles
of high voltage-activated (HVA) calcium channels in excitatory
neurotransmitter release and pain inhibition (24, 44–47), it would
be interesting to examine whether BAM 8–22 inhibits HVA cal-
cium current in small DRG neurons through MrgprC11.
Alternatively, either of two circuit mechanisms could also ex-
plain the inhibitory role of Mrgprs in persistent pain. First,
MrgprC11 ligands may activate DRG neurons that synapse onto
inhibitory interneurons located in the substantia gelatinosa (lam-
ina II) of the spinal cord. Such a mechanism would be consistent
with the fact that these ligands increase intracellular calcium in
cultured DRG neurons (11). This local inhibitory circuit has been
identiﬁed by previous studies (48) and has been suggested to re-
ceive input from relatively large-diameter, more rapidly conduct-
ingCﬁbers. BecauseMrgprs are expressed in largeCﬁber neurons
(diameter = 20–25 μm) that centrally project to lamina II (9, 49),
Mrgpr-expressing neurons may be engaged in this inhibitory
circuitry. Alternatively, the activation of Mrgprs may lead to the
release of inhibitory neurotransmitters or neuromodulators onto
excitatory second-order neurons, thereby inhibiting the pain path-
way. PKC-γ interneurons, which may contribute to pathological
pain, might also play a role in BAM 8–22-induced pain inhibition
and should be investigated in future studies (50–52).
In summary, the present results together with previous data
(11) suggest that certain Mrgprs (mouse MrgprC11 and human
MrgprX1) may constitute an inhibitory mechanism for patho-
logical pain and spinal neuronal sensitization, although additional
experiments are required to determine the underlying cellular and
molecular mechanisms. Because human MrgprX1 expression is
restricted to DRG neurons, speciﬁc agonists of this receptor
might provide relief from chronic pain while producing few side
effects. If so, then such agonists could represent a class of anal-
gesic agents for the treatment of patients with chronic pain.
Experimental Procedures
Production of Mrgpr-ClusterΔ−/−Mice. Thedeletionof a cluster ofMrgpr genes
in themouse germline was described in a previous study (11). Brieﬂy, chimeric
M Mrgpr-clusterΔ−/− (KO) mice were produced by blastocyst injection of
positive embryonic stem cells. The KO mice were generated by mating chi-
meric mice to C57BL/6 mice. Mice were backcrossed to C57BL/6 mice for at
least ﬁve generations. The Mrgpr-clusterΔ−/− mice were fertile, appeared
healthy, and were indistinguishable by their behavior and appearance from
the WT littermates.
CCI Model of Neuropathic Pain in Mice. A CCI at the left sciatic nerve was in-
duced in adult male mice. Inhalation anesthesia was induced with a constant
level of isoﬂurane (2.0%) delivered through a nose cone. Under aseptic
conditions, the left sciatic nerve at the middle thigh level was separated from
the surrounding tissue and loosely tied with three nylon sutures (9-0 non-
absorbable monoﬁlament; S&T AG). The distance between two adjacent
ligatures was around 0.5 mm. None of the mice displayed autotomy or
exhibited marked motor deﬁcits.
Behavioral Studies. All behavioral tests were performed by an experimenter
blinded to the genotype. Themice used in the tests were 2- to 3-mo-oldmales
(20–30 g). All experiments were performed under the protocol approved by
the Animal Care and Use Committee of the Johns Hopkins University School
of Medicine.
Formalin test. Formalin (5 μL 2% formalin in PBS) was injected into the plantar
region of one hind paw, and spontaneous pain behavior (licking and biting)
was recorded for 60 min as previously described (23, 37).
CFA-induced heat hyperalgesia. The intraplantar region of one hind paw of each
mouse was injected with 6 μL 50% CFA solution in saline. Thermal-pain sen-
sitivity was assessed by recording PWL on exposure to a deﬁned radiant-heat
stimulus (Hargreaves test) before CFA injection and 30min after injection (41).
Tail-immersion test. Mice were gently restrained in a 50-mL conical tube that
the mice voluntarily entered. The protruding one-third of the tail was then
dipped into a 50 °C water bath. Latency to respond to the heat stimulus with
vigorous ﬂexion of the tail was measured three times and averaged.
CCI-induced mechanical allodynia. Mechanical sensitivity was assessed with the
von Frey test by the frequency method (53). Two calibrated von Frey mono-
ﬁlaments (low force = 0.07 g; high force = 0.45 g) were used. Each von Frey
ﬁlament was applied perpendicularly to the plantar side of each hind paw for
∼1 s; the stimulation was repeated 10 times to both hind paws. The occur-
rence of pawwithdrawal in each of these 10 trials was expressed as a percent
response frequency: PWF = (number of paw withdrawals/10 trials) × 100%.
Drug and Intrathecal Injection. BAM 8–22 was purchased from Tocris and sus-
pended in 0.9% saline. The drug was injected intrathecally under brief iso-
ﬂurane (1.5%)anesthesia to reduce stress. A30-gauge, 0.5-inneedle connected
toa10-μL syringewas inserted intoone sideof theL5or L6 spinousprocess at an
angleof∼20°above the vertebral columnand slipped into thegroovebetween
the spinous and transverse processes. The needlewas moved carefully forward
to the intervertebral space. A tail ﬂick indicated that the tip of the needle was
inserted into the subarachnoid space.
Electrophysiological Recording of WDR Neurons Electrophysiological recording
of WDR neurons in the dorsal horn of the spinal cord was performed by an
experimenter blinded to the genotype as previously described (20). Micewere
paralyzed with pancuronium bromide (0.15 mg/kg i.p.) during neurophysio-
logical recording. Throughout the experiment, anesthesia was maintained
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with a constant level of isoﬂurane (1.5%) carried inmed-air. A spinal unit with
a cutaneous receptive ﬁeld located in the plantar area of the hind paw was
located by applying mechanical stimuli. WDR neurons were deﬁned as those
that responded to both innocuous and noxious mechanical stimuli and that
had increasing rates of response to increasing intensities of stimuli. Electrical
stimuli were applied through a pair of ﬁne needles inserted s.c. across the
central plantar area of the hind paw0.3–0.4 cm apart. Extracellular recordings
of individual neurons were obtained by using ﬁne-tip (<1.0 μm) paralyn-
coated tungstenmicroelectrodes (8mΩ at 1 kHz). BAM8–22 or vehicle control
was applied directly to the exposed surface of the spinal cord at the recording
segment in a volume of 30–50 μL after predrug tests. The effects of BAM 8–22
on the spontaneous activity of WDR neurons were examined within 0–10 min
after application. The evoked neuronal responses were recorded 10–30 min
after drug application. Only one neuron in each animal was used to test the
drug effects. The postdrug responses were compared with the predrug
responses, allowing each neuron to act as its own control.
Data Analysis. The number of action potentials evoked by graded electrical
stimuli was compared between two genotypes by a two-way mixed-model
ANOVAwith Fisher’s protected least signiﬁcant difference (LSD) post hoc test.
Student t test was used to compare the recording depth, activation threshold,
latency of the ﬁrst A ﬁber-mediated response, and latency of the ﬁrst C ﬁber-
mediated response between the two groups. For windup, the raw data were
the number of action potentials in the C component evoked by each stimulus
in a train of repetitive electrical stimuli. Because the number of action
potentials in the C component varies among WDR neurons, the raw data for
each neuron were normalized to the ﬁrst response in each trial (input) and
thenaveraged.A two-waymixed-modelANOVAwasused to comparewindup
and averaged C component responses to the last 10 stimuli (7–16) of the trial
between the two genotypes and between pre- and postdrug conditions. Data
are presented as mean ± SEM. P < 0.05 was considered signiﬁcant.
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